Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

959
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
959
Types of Intermediate Filaments01:31

Types of Intermediate Filaments

3.7K
The intermediate filaments are an essential component of the cytoskeleton. Presently six types of intermediate filament have been identified. Type I and II are acidic and basic keratin proteins. Type III is of mesodermal origin and comprises four proteins: vimentin, desmin, glial fibrillary acidic protein (GFAP), and peripherin. Vimentin is commonly found in mesenchymal cells, desmin in muscle cells, GFAP in astrocytes, while peripherin is found in peripheral nervous system neurons (PNS). Type...
3.7K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

800
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
800
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Autoimmune Disorders01:29

Autoimmune Disorders

460
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
460
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

9
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
9

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics Associated With EuroLupus Versus Modified National Institutes of Health Cyclophosphamide Regimen Use in Children and Young Adults With Lupus Nephritis.

ACR open rheumatology·2025
Same author

Artistry in Scientific Writing.

Plastic and reconstructive surgery·2024
Same author

Simultaneous Co-surgeon Deep Inferior Epigastric Perforator (DIEP) Flap Breast Reconstructions: Feasibility and Clinical Outcomes.

Annals of surgical oncology·2024
Same author

Expansion of extrafollicular B and T cell subsets in childhood-onset systemic lupus erythematosus.

Frontiers in immunology·2023
Same author

Renal Response Outcomes of the EuroLupus and National Institutes of Health Cyclophosphamide Dosing Regimens in Childhood-Onset Proliferative Lupus Nephritis.

Arthritis & rheumatology (Hoboken, N.J.)·2023
Same author

Opioid Coprescribing with Sedatives after Implant-Based Breast Reconstruction.

Plastic and reconstructive surgery·2022

Related Experiment Video

Updated: Jul 13, 2025

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.4K

Type I Interferonopathies: A Clinical Review.

Christine S Wang1

  • 1Department of Pediatric Rheumatology, C.S. Mott Children's Hospital, University of Michigan, 1500 East Medical Center Drive SPC 5718, Ann Arbor, MI 48109, USA.

Rheumatic Diseases Clinics of North America
|October 11, 2023
PubMed
Summary
This summary is machine-generated.

This review covers Type I interferonopathies, detailing when to test, their clinical signs, genetic causes, and available treatments for better patient management.

Keywords:
Aicardi-goutières syndromeInborn errors of immunityInterferonopathiesMonogenic lupusType I interferonopathy

More Related Videos

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.1K
Rescue of Recombinant Newcastle Disease Virus from cDNA
10:55

Rescue of Recombinant Newcastle Disease Virus from cDNA

Published on: October 11, 2013

19.4K

Related Experiment Videos

Last Updated: Jul 13, 2025

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.4K
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.1K
Rescue of Recombinant Newcastle Disease Virus from cDNA
10:55

Rescue of Recombinant Newcastle Disease Virus from cDNA

Published on: October 11, 2013

19.4K

Area of Science:

  • Immunology
  • Genetics
  • Clinical Medicine

Background:

  • Type I interferonopathies are a group of rare genetic disorders.
  • These conditions are characterized by the dysregulation of the type I interferon immune pathway.
  • Understanding these disorders is crucial for timely diagnosis and management.

Purpose of the Study:

  • To outline the clinical indicators for evaluating patients for Type I interferonopathies.
  • To review the diverse clinical presentations and underlying molecular genetic defects.
  • To discuss the current therapeutic strategies for managing these conditions.

Main Methods:

  • This is a review article.
  • Information was gathered from existing literature on Type I interferonopathies.
  • Key aspects discussed include diagnostic criteria, clinical manifestations, genetic basis, and treatment options.

Main Results:

  • Clinicians should consider evaluation for Type I interferonopathies in patients with specific overlapping clinical features.
  • A wide spectrum of clinical phenotypes exists, linked to various molecular defects.
  • Current treatments aim to modulate the type I interferon pathway or manage specific symptoms.

Conclusions:

  • Early recognition and appropriate genetic testing are vital for diagnosing Type I interferonopathies.
  • Tailored treatment approaches based on the specific molecular defect and clinical phenotype are essential.
  • Further research is needed to develop more targeted therapies.